Bio Impact Capital LLC Amicus Therapeutics, Inc. Transaction History

Bio Impact Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$11.43 - $14.24 $35,284 - $43,958	3,087 Added 0.43%	718,970 $8.47 Million
Q4 2023 Feb 13, 2024	BUY	$9.97 - $14.52 $1.99 Million - $2.9 Million	199,744 Added 38.7%	715,883 $10.2 Million
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $1.37 Million - $1.7 Million	127,847 Added 32.93%	516,139 $6.48 Million
Q1 2023 May 12, 2023	SELL	$10.91 - $13.54 $132,207 - $164,077	-12,118 Reduced 3.03%	388,292 $4.31 Million
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $73,818 - $94,792	7,464 Added 1.9%	400,410 $4.89 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $1.01 Million - $1.31 Million	-102,657 Reduced 20.71%	392,946 $4.1 Million
Q1 2022 May 13, 2022	SELL	$7.89 - $12.48 $139,889 - $221,270	-17,730 Reduced 3.45%	495,603 $4.69 Million
Q4 2021 Feb 11, 2022	SELL	$9.82 - $12.44 $326,269 - $413,319	-33,225 Reduced 6.08%	513,333 $5.93 Million
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $4.78 Million - $6.47 Million	546,558 New	546,558 $5.22 Million

278

324M

260K

261K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.99B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.